Suppr超能文献

ST11-K64 高毒力株的出现对老年患者构成严重临床威胁。

Emergence of Hypervirulent ST11-K64 Poses a Serious Clinical Threat in Older Patients.

机构信息

Department of Clinical Laboratory, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Department of Medical Technology, Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

出版信息

Front Public Health. 2022 Mar 4;10:765624. doi: 10.3389/fpubh.2022.765624. eCollection 2022.

Abstract

The carbapenem-resistant hypervirulent (CR-hvKP) poses a severe therapeutic challenge to global public health, and research on CR-hvKP in older patients remain limited. In this study, we aimed to investigate the clinical and molecular characteristics and risk factors of CR-hvKP infections in older patients. We retrospectively investigated older patients with carbapenem-resistant (CRKP) infections in the intensive care unit (ICU) between January 2020 and December 2020. The clinical data, and microbiological data including antimicrobial susceptibility testing, phenotype experiment and detection of carbapenemases, string test, virulence genes, capsular serotype-specific (cps) genes, and multilocus sequence typing, of the CR-hvKP group defined by the presence of any one of the virulence genes, including , and were compared with those of CR-non-hvKP strains. Of the 80 CRKP strains, 51 (63.8%) met the definition of CR-hvKP. The main mechanism of resistance to carbapenems was the presence of the gene. Sequence type (ST)11 (81.3%, 65/80) and ST15 (16.3%, 13/80) were the most common STs in CRKP strains. The minimum inhibitory concentration (MIC) values of the CR-hvKP group against the six tested antibiotics (ceftazidime, ceftazidime-avibactam, imipenem-avibactam, tigecycline, levofloxacin, and Cefoperazone-Sulbactam) exhibited elevated levels than the CR-non-hvKP group. Ceftazidime and imipenem by combining avibactam (4 μg/mL) significantly decreased the MIC values more than 16-fold than ceftazidime and imipenem alone against carbapenemase (KPC)-2-producing . Cardiovascular disease [odds ratio (OR) = 11.956] and ST11-K64 (OR = 8.385) appeared to be independent variables associated with CR-hvKP infection by multivariate analysis. In conclusion, higher MICs of the last line antibiotic agents (ceftazidime-avibactam, tigecycline) might be a critical consideration in the clinical management of older patients where the concentration of these toxic antibiotics matters because of underlying comorbidities. Caution regarding KPC-2-producing ST11-K64 CR-hvKP as being new significant "superbugs" is required as they are widespread, and infection control measures should be strengthened to curb further dissemination in nosocomial settings in China.

摘要

耐碳青霉烯类超毒力 (CR-hvKP) 对全球公共健康构成严重治疗挑战,针对老年患者的 CR-hvKP 研究仍然有限。在这项研究中,我们旨在研究老年患者耐碳青霉烯类 (CRKP) 感染的临床和分子特征以及危险因素。我们回顾性调查了 2020 年 1 月至 2020 年 12 月期间重症监护病房 (ICU) 中耐碳青霉烯类 (CRKP) 感染的老年患者。比较了 CR-hvKP 组 (通过存在任何一种毒力基因定义,包括 、 和 )与 CR-non-hvKP 株的临床数据和微生物学数据,包括抗菌药物敏感性试验、表型实验和碳青霉烯酶检测、串联试验、毒力基因、荚膜血清型特异性 (cps) 基因和多位点序列分型。耐碳青霉烯类的主要机制是 基因的存在。80 株 CRKP 中,51 株 (63.8%,65/80)符合 CR-hvKP 的定义。CRKP 株中最常见的 ST 型为 ST11(81.3%,65/80)和 ST15(16.3%,13/80)。CR-hvKP 组对 6 种测试抗生素 (头孢他啶、头孢他啶-阿维巴坦、亚胺培南-阿维巴坦、替加环素、左氧氟沙星和头孢哌酮-舒巴坦) 的最低抑菌浓度 (MIC) 值高于 CR-non-hvKP 组。头孢他啶和亚胺培南联合阿维巴坦 (4μg/ml) 对产 KPC-2 的 显著降低 MIC 值超过 16 倍,而头孢他啶和亚胺培南单独使用。多变量分析显示,心血管疾病 (比值比 (OR)=11.956) 和 ST11-K64 (OR=8.385) 似乎是 CR-hvKP 感染的独立变量。总之,由于潜在的合并症,最后一线抗生素 (头孢他啶-阿维巴坦、替加环素) 的 MIC 值较高可能是老年患者临床管理的一个关键考虑因素。由于这些毒性抗生素的浓度很重要,因此需要对产 KPC-2 的 ST11-K64 CR-hvKP 保持警惕,因为它们广泛存在,应加强感染控制措施,以遏制其在中国医院环境中的进一步传播。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2782/8930914/17e31d814cf4/fpubh-10-765624-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验